Loading…
← CockpitCompetitor Analysis › 301333.SZ R&G PharmaStudies Co., Ltd. Class AOpen in the cockpit ↗

R&G PharmaStudies Co., Ltd. Class A301333.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum strong 63
Mkt cap
$722M
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$18.1M
20-day average traded
Fwd P/E
37.9×
forward earnings
ROIC−WACC
+16.0 pp
WACC 9.3%
Hurdle
+6 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥51.05
1D-1.1%
1W-10.2%
1M-6.8%
3M-19.7%
6M-11.2%
YTD-14.3%
1Y-25.1%
ATR %6.5%
52w lowhigh44.4% off high

What R&G PharmaStudies does

Employees: 2,645

R&G PharmaStudies at a glance

Size R&G PharmaStudies (301333.SZ) is a China Health Care company (Biotechnology) with a market value of $722M, the 2831st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.05 on 18 Nov 2026.

Performance Over six months the shares fell 11.2%, against -22.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 21.3% over the last twelve months (peer median +7.1%); the operating margin is 11.3% (peer median -99.9%).

Valuation It trades at 37.9× forward earnings against a peer median of 19.4× (most expensive of 4).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 16.0 points above its cost of capital (9.3% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026301333.SZ 90Peer median 78
Six months, rebased to 100: R&G PharmaStudies against the median of its 20 peers (local-currency closes).

R&G PharmaStudies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥957MCN¥847MCN¥741MCN¥718MCN¥635M
Revenue growth—+14%+3%+13%—
Gross profitCN¥317MCN¥289MCN¥270MCN¥280MCN¥229M
EBITDAn/aCN¥160MCN¥157MCN¥168MCN¥141M
Net incomeCN¥117MCN¥137MCN¥140MCN¥163MCN¥113M
Free cash flowCN¥107MCN¥116MCN¥158MCN¥198MCN¥119M
Capital expenditureCN¥16.0MCN¥19.3MCN¥20.0MCN¥19.9MCN¥20.8M
Total debtCN¥50.1MCN¥17.9MCN¥71.9MCN¥8.86MCN¥15.7M

Quarterly statements and history in the cockpit →

R&G PharmaStudies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%ATTOSLDB002038AURA3015209887SNDXGLUE77299966688221301333.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. R&G PharmaStudies is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%20×30×6885269966GERN301333.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. R&G PharmaStudies is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002038301520688526688221301333.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. R&G PharmaStudies is the large dot.

R&G PharmaStudies competitors and peer comparison

How R&G PharmaStudies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

R&G PharmaStudies against its 20 peers (data as of 18 Nov 2026)
Measure301333.SZPeer medianRank in peer set
1-month return-6.8%-7.2%10th highest of 21
6-month return-11.2%-22.6%7th highest of 19
Distance from 52-week high-44.4%-47.7%7th highest of 21
Revenue growth (TTM)+21.3%+7.1%6th highest of 15
Operating margin11.3%-99.9%3rd highest of 17
Forward P/E37.9×19.4×most expensive of 4
Growth the price implies (Req g, 7 yrs)17.3%24.1%3rd least demanding of 5
Growth delivered (Del g)+11.8%+8.5%3rd highest of 5
Hurdle (Req g minus delivered)+5.5 pp+12.1 pp3rd least demanding of 5
ROIC minus cost of capital+16.0 pp-15.9 pp2nd highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%37.9×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%n/an/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%n/an/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%n/a-13.5%-10.9%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%n/an/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%n/a44.8%+14.7%
Inventiva IVA.PAFrance$763M-36%-100%-307,063%n/an/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%n/an/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%n/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%n/an/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%19.4×7.8%+2.4%
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%24.0×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%n/a40.3%+21.5%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%n/an/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%n/an/an/a
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a

Questions

Which companies are R&G PharmaStudies's closest peers?
The cockpit's peer set: Apnimed (APMD), Shaanxi Micot Pharmaceutical Technology (2335.HK), Attovia Therapeutics (ATTO), Solid Biosciences (SLDB), Beijing SL Pharmaceutical (002038.SZ), Aura Biosciences (AURA), Prime Medicine (PRME), Anhui Wanbang Pharmaceutical Technology (301520.SZ).
Is R&G PharmaStudies expensive compared with its peers?
On forward p/e it trades at 37.9× against a peer median of 19.4×, most expensive of 4 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has R&G PharmaStudies stock performed?
Over six months to 18 Nov 2026 the shares returned -11.2% against -22.6% for the median peer; over one year -25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.